ESMO 2017: 14 years of progress in mCRPC – New avenues for immunotherapy and precision medicine: Invited Discussant

Madrid, Spain ( Dr. Ronald De Wit concluded the prostate cancer poster discussion session with an invited discussant presentation assessing four high-level abstracts presented at ESMO 2017 in Madrid, Spain. The four posters included “Safety and Immunogenicity of a DNA-vaccine Immunotherapy in Men with Biochemically (PSA) Relapsed Prostate Cancer” by Dr. Neal Shore, “Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer” by Dr. Diletta Di Mitri, “Phase I, Open-label, Dose-Finding Study of GSK2636771, a phosphoinositide 3-kinase β inhibitor, in Combination with Enzalutamide in Male Subjects with Metastatic Castration-Resistant Prostate Cancer” by Pasquale Rescigno and “Phase I study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer” by Dr. Michael Morris.

ESMO 2017: Prostate Cancer Poster Discussion: Invited Discussant

Madrid, Spain ( Dr. David Olmos from Madrid, Spain provided a discussion regarding two high-level posters at this morning’s prostate cancer session at ESMO 2017. The two studies included “DNA repair gene panel mutations in young onset and aggressive v non-aggressive prostate cancer cases in the UK” [1] by Dr. Eeles and colleagues and “Prognostic Associations of PSA Decline with Survival, Radiographic Response and Progression in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide” [2] by Dr. Armstrong and colleagues.

ESMO 2017: Initial Results from AQUARiUS, a Prospective, Observational, Multi-Centre Phase IV Study Assessing Patient-Reported Outcomes in mCRPC Patients Treated with Abiraterone Acetate plus prednisone or Enzalutamide

Madrid, Spain ( Antoine Thiery-Vuillemin presented initial results from a patient reported outcomes (PROs) study among men receiving either abiraterone + prednisone or enzalutamide. For mCRPC patients prior to chemotherapy, both abiraterone + prednisone [1] and enzalutamide [2] have demonstrated improved overall survival (OS) compared to placebo.

ESMO 2017: Cabazitaxel followed by ADT improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A Randomized, Open Label, Phase III, Multicenter trial

Madrid, Spain ( Dr. Andrén and colleagues from Sweden presented results of their clinical trial assessing cabazitaxel followed by ADT among men with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) at today’s poster session at ESMO 2017 in Madrid, Spain. Patients with newly diagnosed mHSPC have a poor prognosis with a 3-year overall survival (OS) rate of 50%.

ESMO 2017: Assessment of health-related quality of life in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 vs 25 mg/m2 in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC)

Madrid, Spain ( Dr. Eisenberger and colleagues presented health-related quality of life (HRQL) results comparing reduced dose cabazitaxel to standard dose cabazitaxel in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) at today’s ESMO 2017 poster session. PROSELICA was a phase III study assessing the effect of cabazitaxel 20 mg/m2 vs cabazitaxel 25 mg/m2 on overall survival (OS) in a non-inferiority study of patients with mCRPC [1].

ESMO 2017: Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Madrid, Spain ( Dr. Stenzl and colleagues from Germany presented results of their phase I/IIB trial assessing the mRNA based cancer immunotherapy CV9104 for patients with metastatic castration-resistant prostate cancer (mCRPC) at today’s poster session at ESMO 2017.

ESMO 2017: Management of M0 Patient with Rising PSA: How can PET imaging help?

Madrid, Spain ( Dr. Haberkorn from Germany provided a discussion assessing how PET imaging can assist with monitoring and treating the M0 patient at the symposium on the Management of the M0 patient with rising PSA at ESMO 2017. The rationale for PSMA targeting prostate cancer is that PSMA expression increases progressively in higher grade tumors, metastatic disease, and hormone-refractory prostate cancer, while at the same time maintaining normal expression patterns in normal tissue. These molecules have high specificity for receptors, fast circulation through the body, are easy to produce and label, and have high stability, and no host immune response. 

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.